{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:59:33Z","timestamp":1790189973370,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:p>Ixekizumab, a monoclonal antibody that neutralizes interleukin-17A, was approved by the Food and Drug Administration in 2016 for the treatment of plaque psoriasis and psoriatic arthritis. This study assesses the postmarketing safety profile of ixekizumab. Data from the Food and Drug Administration Adverse Event Reporting System were analyzed using disproportionate analysis methods, including the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network, and the multi-item gamma Poisson shrinker algorithms. A total of 26,867 reports identified ixekizumab as the \u201cprimary suspected\u201d drug. These ixekizumab-related adverse events (AEs) were observed across 27 targeted system organ classes. Notably, upon satisfying the criteria of all 4 algorithms, we identified 23,595 signals spanning 167 preferred terms. The most common signals were injection site reaction (broad), psoriasis, COVID-19, nasopharyngitis, urticaria, and sinusitis. New AEs identified include ear infections, tooth infections, necrotizing fasciitis, lichen planus, and pyoderma gangrenosum. The number of reports exhibited significant monthly fluctuations. There was a noticeable downward trend in reports each May, whereas December consistently showed an increase in reports. In recent report data, a trend of decrease has been observed starting from 2023. While our findings align with clinical trial results and the product label, our data revealed some new AEs. Noteworthy is the decline in reports starting from 2023.<\/jats:p>","DOI":"10.1097\/md.0000000000044373","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:00:30Z","timestamp":1757970030000},"page":"e44373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis of ixekizumab-associated adverse events in the FAERS database: A real-world pharmacovigilance study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4088-5945","authenticated-orcid":false,"given":"Jia","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Suining Central Hospital, Suining, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The People\u2019s Hospital of Kaijiang, Dazhou, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Emergency, The First Hospital of Jilin University, Changchun, Jilin Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/14740338.2020.1709440","article-title":"The safety of ixekizumab in psoriasis drug therapy.","volume":"19","author":"Puig","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R2-20260923","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials.","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet (London, England)"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial.","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis.","volume":"82","author":"Warren","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40265-016-0579-y","article-title":"Ixekizumab: first global approval.","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials.","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet (London, England)"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/1744666X.2020.1803063","article-title":"Ixekizumab for the treatment of ankylosing spondylitis.","volume":"16","author":"Huang","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jdv.15098","article-title":"Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients.","volume":"33","author":"Wu","year":"2019","journal-title":"J Eur Academy Dermatol Venereol"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies.","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis.","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R14-20260923","first-page":"1838","article-title":"Ab0744 efficacy of ixekizumab in active psoriatic arthritis (PSA) patients with axial pain starting before age 45: a subgroup analysis of spirit-P1 and spirit-P2 phase 3 clinical trials.","volume":"78","author":"Deodhar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/annrheumdis-2020-eular.2027","article-title":"Thu0395 efficacy of ixekizumab on disease activity and quality of life in patients with active non-radiographic axial spondyloarthritis and objective signs of inflammation, stratified by baseline CRP\/sacroiliac joint MRI status.","volume":"79","author":"Maksymowych","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/pds.5265","article-title":"More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis.","volume":"30","author":"Hauben","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pds.5555","article-title":"More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching.","volume":"32","author":"Hung","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12911-020-01280-1","article-title":"How to interact with medical terminologies? Formative usability evaluations comparing three approaches for supporting the use of MedDRA by pharmacovigilance specialists.","volume":"20","author":"Marcilly","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fphar.2019.00050","article-title":"Semantic queries expedite MedDRA terms selection thanks to a dedicated user interface: A pilot study on five medical conditions.","volume":"10","author":"Souvignet","year":"2019","journal-title":"Front Pharmacol"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1074248420984082","article-title":"Use of disproportionality analysis to identify previously unknown drug-associated causes of cardiac arrhythmias using the food and drug administration adverse event reporting system (FAERS) database.","volume":"26","author":"Moreland-Head","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/annrheumdis-2021-222027","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","article-title":"Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial.","volume":"158","author":"Paller","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R27-20260923","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2014.07.048","article-title":"A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.","volume":"71","author":"Gordon","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jaad.2018.03.047","article-title":"Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.","volume":"79","author":"Zachariae","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R29-20260923","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study.","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/annrheumdis-2011-201208","article-title":"Does the change in season affect disease activity in patients with psoriatic arthritis?","volume":"71","author":"Touma","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R31-20260923","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1346-8138.1998.tb02357.x","article-title":"Factors influencing psoriasis: an analysis based upon the extent of involvement and clinical type.","volume":"25","author":"Park","year":"1998","journal-title":"J Dermatol"},{"key":"R32-20260923","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab citrate-free formulation: results from two clinical trials.","volume":"39","author":"Chabra","year":"2022","journal-title":"Adv Ther"},{"key":"R33-20260923","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"R34-20260923","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R35-20260923","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/bjd.15723","article-title":"Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"key":"R36-20260923","doi-asserted-by":"crossref","first-page":"545","DOI":"10.23736\/S2784-8671.20.06580-3","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.","volume":"156","author":"Rodr\u00edguez-Cerdeira","year":"2021","journal-title":"Ital J Dermatol Venereol"},{"key":"R37-20260923","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R38-20260923","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R39-20260923","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R40-20260923","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers.","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:01:21Z","timestamp":1790186481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":40,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044373","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2024-07-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}